solute carrier family 38 member 4Genealiases: ATA3 · NAT3 · PAAT · SNAT4
Q-omics provides the consensus-scored SLC38A4 profile across patient tissues and cancer cell-line models. SLC38A4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, SLC38A4 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, SLC38A4 RNA expression shows 17,063 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LIHC, COAD, and THYM as cancer lineages where SLC38A4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC38A4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC38A4 survival associations across molecular data types. SLC38A4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC38A4 RNA expression–survival associations across cancer types. High SLC38A4 expression shows unfavorable associations in KIRP, UVM and OV, but favorable associations in LIHC, UCS and THCA. The LIHC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for SLC38A4 RNA expression.
This table summarizes SLC38A4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC38A4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC38A4 shows lower tumor expression in COAD, KIRC, LIHC, KICH and CHOL and higher tumor expression in LUAD. The COAD box plot shows higher SLC38A4 RNA expression in normal versus tumor tissue (log2 FC = −2.401, t-test p < 0.001).
This table shows molecular features associated with SLC38A4 in patient tissues and cancer cell lines. In patient samples, SLC38A4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC38A4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
